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Background. This study evaluated the impact of age and pneumococcal vaccination on the density of pneu-
mococcal nasopharyngeal carriage.
Methods. A cluster-randomized trial was conducted in rural Gambia. In 11 villages (the vaccine group), all
residents received 7-valent pneumococcal conjugate vaccine (PCV-7), while in another 10 villages (the control
group), only children <30 months old or born during the study period received PCV-7. Cross-sectional surveys
(CSSs) were conducted to collect nasopharyngeal swabs before vaccination (baseline CSS) and 4, 12, and 22
months after vaccination. Pneumococcal density was deﬁned using a semiquantitative classiﬁcation (range, 1–4)
among colonized individuals. An age-trend analysis of density was conducted using data from the baseline CSS.
Mean pneumococcal density was compared in CSSs conducted before and after vaccination.
Results. Mean bacterial density among colonized individuals in the baseline CSS was 2.57 for vaccine-type
(VT) and non–vaccine-type (NVT) pneumococci; it decreased with age (P < .001 for VT and NVT). There was a
decrease in the density of VT carriage following vaccination in individuals older than 5 years (from 2.44 to 1.88;
P = .001) and in younger individuals (from 2.57 to 2.11; P = .070) in the vaccinated villages. Similar decreases in
density were observed with NVT within vaccinated and control villages. No signiﬁcant differences were found
between vaccinated and control villages in the postvaccination comparisons for either VT or NVT.
Conclusions. A high density of carriage among young subjects might partly explain why children are more
efﬁcient than adults in pneumococcal transmission. PCV-7 vaccination lowered the density of VT and of NVT
pneumococcal carriage in the before-after vaccination analysis.
Clinical Trials Registration. ISRCTN51695599.
Prevention of pneumococcal disease is a public health
priority [1]. Nasopharyngeal pneumococcal carriage
plays an important role in the pathogenesis of invasive
pneumococcal disease (IPD) and pneumococcal trans-
mission. The effectiveness of pneumococcal conjugate
vaccines (PCVs) in preventing disease due to vaccine-
serotype (VT) pneumococci is due in large measure to
their impact on nasopharyngeal carriage in both vacci-
nees and their contacts [2–5]. Such a reduction is
sometimes accompanied by an increase in carriage of
non–vaccine-serotype (NVT) pneumococci [2–7].
How this increase in NVT pneumococcal carriage is
brought about is still not fully understood. Elimination
of VT pneumococci from the nasopharynx might open
up an ecological niche that can be colonized by NVT
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pneumococci in the face of reduced competition from VT
pneumococci [3, 5–7]. Alternatively, apparent replacement
could be an artifact due to the “unmasking” of NVT serotypes
as reduction in VT pneumococci makes it easier to detect NVT
[6–9]. Because the commonly used serotyping methods require
that only a few colonies are assessed, investigators are unlikely
to detect cocolonization of serotypes present at low density.
Increasing attention is being paid to the nasopharyngeal bac-
terial load (or density) of pneumococcal colonization [10, 11].
Although data on the inverse association between the preva-
lence of pneumococcal nasopharyngeal carriage and age are
widely available, we are unaware of any data on the association
of pneumococcal nasopharyngeal density and age. PCVs may
have an effect on carriage density among those who remain
colonized, inﬂuencing their susceptibility to pneumonia and
their ability to transmit the infection [6].
The aims of this study were to evaluate the impact of age—
a surrogate for naturally acquired immunity—and 7-valent
PCV (PCV-7) vaccination on the density of VT and NVT na-
sopharyngeal carriage recorded during a cluster-randomized
trial (CRT) conducted in rural Gambia. All residents of 11 vil-
lages were vaccinated with PCV-7, whereas in 10 villages only
young children received PCV-7 [12]. The prevalence of car-
riage with VT pneumococci fell after vaccination in all age
groups and both study arms. There was little change in the
prevalence of NVT carriage following vaccine introduction.
METHODS
Study Population
The study was conducted in 21 villages in the Sibanor area in
the Western Region of Gambia. The combined population of
the selected villages was 5441 in June 2006 [12], with 80–660
inhabitants per village. The prevalence of HIV infection
among pregnant women attending the local hospital (in
Sibanor) between 2000 and 2001 was 3% [13]. Other charac-
teristics of the study population are described elsewhere [14].
The study was approved by the joint Medical Research
Council (MRC)/Gambia Government Ethics Committee and
by the ethics committee of the London School of Hygiene and
Tropical Medicine. The conduct of the trial was guided by a
data safety and monitoring board.
Trial Design
A comprehensive description of the trial design, randomization,
and cross-sectional surveys (CSS) conducted before and after
vaccination has been presented previously [12]. In brief, in one
group of 11 villages, all individuals older than 30 months re-
ceived 1 dose of PCV-7, whereas in 10 control villages, subjects
older than 30 months received 1 dose of serogroup C meningo-
cococal conjugate vaccine. In both study groups, all children
younger than 30 months and infants born during the course of
the trial received PCV-7 (3 doses at monthly intervals for infants
and 1 dose for children >1 year of age at the time of vaccination).
It was considered unethical not to give PCV-7 to all children
<30 months of age because the efﬁcacy of a 9-valent PCV of
Gambian children was previously shown [15]. PCV-7 vaccina-
tion started in July 2006, and by September the ﬁrst round of
vaccination had been completed (Supplementary Figure 1).
CSSs were conducted before and 4–6 months (CCS-1), 12
months (CCS-2), and 22 months (CCS-3) after vaccination
started, during which nasopharyngeal swabs were collected from
approximately 1200 randomly selected, age-stratiﬁed subjects [12]
(Supplementary Figure 1). In the last survey, only 446 samples
were analyzed because many subjects in study villages had re-
ceived a single dose of azithromycin during the course of the
Gambian National Trachoma Elimination; all 446 samples were
collected before the azithromycin campaign started in any of the
study villages.
Nasopharygeal Samples
Sample collection and laboratory methods were similar during
all surveys. Nasopharyngeal specimens were collected by appli-
cation of a calcium alginate swab to the posterior wall of the
nasopharynx, and swabs were inoculated into vials containing
skim milk-tryptone-glucose-glycerol (STGG) transport medi-
um. Inoculated vials were placed in a cold box and, within 8
hours, were stored at −70°C, in accordance with the World
Health Organization protocol [16].
Laboratory Methods
A total of 10 µL of thawed, inoculated STGG medium was
plated onto gentamicin blood agar (GBA) plates for selective
isolation of Streptococcus pneumoniae and incubated for 18–
24 hours at 35°C in 5% CO2. Pneumococcal identiﬁcation was
based on colony morphology and conventional methods of
characterization (optochin susceptibility and bile solubility
assays) [14]. Inoculated STGG medium was streaked onto the
GBA plates to obtain decreasing inoculum sizes in 4 different
quadrants of a Petri dish, from the ﬁrst quadrant (where the
diluted nasopharyngeal swabs was inoculated) to the fourth
(the last to be covered by the loop) [17]. For samples from
which at least 1 pneumococcal colony was isolated, density
was semiquantitatively categorized as described previously
[17]: category 4, >10 pneumococcal colonies counted in the
fourth quadrant of the Petri dish; category 3, <10 pneumococ-
cal colonies present in the fourth quadrant and >10 in the
third quadrant; category 2, <10 pneumococcal colonies
present in the third quadrant and >10 in the second quadrant;
and category 1, <10 pneumococcal colonies counted in the
second quadrant and any colony present in the ﬁrst quadrant.
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Serotyping was performed at MRC Fajara with capsular and
factor typing sera (Statens Serum Institut, Copenhagen,
Denmark), using a modiﬁed latex agglutination assay [18].
Equivocal results were conﬁrmed by the Quellung reaction.
Pneumococci were classiﬁed as follows: VT serotypes included
those in PCV-7 (4, 6B, 9V, 14, 18C, 19F, and 23F) and sero-
type 6A; NVT comprised other pneumococcal serotypes not
included in the above classiﬁcation, as well as nontypeable
pneumococci. All detected serotypes were included in the
analysis for subjects carrying >1 serotype.
Analysis
The primary end points for the analysis were the density of VT
and NVT pneumococci in nasopharyngeal swabs. Mean pneu-
mococcal density among pneumococcal nasopharyngeal carriers
was calculated before and after vaccination. Data from the post-
vaccination surveys (CSS-1–3) were combined to improve the
statistical power and to reduce the number of comparisons,
thereby limiting multiple testing. In addition, there was no con-
sistent difference in pneumococcal density among the postvacci-
nation surveys. Analyses were based on cluster-level summaries
(ie, village means), since the number of clusters is small and
because statistical models that allow for clustering (eg, random
effects or generalized estimating equations) may be less robust
under these circumstances [19]. The difference between mean
density in control and vaccinated villages was adjusted for base-
line density, using analysis of covariance. The comparison was
performed separately for children ≤5 years of age and for indi-
viduals >5 years of age when the sample had been collected. We
tested for interaction between age and trial arm, using the
method of Cheung et al [20]. A paired t test was used to
compare mean density in vaccinated villages following vaccina-
tion with baseline density, and a paired t test was also used to
compare the differences (baseline vs postvaccination) between
age groups (ie, to test for interaction between age and time).
RESULTS
Samples
Analyses were based on 4792 samples (2094 obtained during
the baseline CSS and 2698 collected during postvaccination
CSSs). Overall, 136 samples were excluded from the analyses
of the postvaccination surveys; 102 samples were from chil-
dren <30 months of age, since children in this age group had
received PCV-7 regardless of the trial arm, and 24 samples
were from children sampled before vaccination.
The overall prevalence of pneumococcal carriage dropped
from 71% in the baseline CSS to 44% in the postvaccination
surveys [12]. Density data were available for >95% of the
pneumococcal-colonized individuals (Table 1). The distribu-
tion of pneumococcal carriers is presented in Table 2.
Baseline Pneumococcal Carriage Density
Mean density among colonized individuals in the baseline
CSS decreased with age (P < .001 for VT, NVT, and any car-
riage) (Figure 1). Most pneumococcal carriers (83%) had a
density of carriage of >1, and this was similar among VT
(87%) and NVT (82%) carriers (Figure 2). There was no diffe-
rence in overall density by sex (P = .560) for either VT
(P = .231) or NVT carriage (P = .727).
Density varied by serotype (P < .001 in both age groups)
(Supplementary Table 1). In the youngest age group, the
density of VT serotypes ranged from 2.38 to 4.00, and the
density of NVT ranged from 2.33 to 3.50. Among older sub-
jects, densities were lower than those among young children
for nearly all serotypes, ranging from 2.27 to 2.50 for VT and
from 2.17 to 2.70 for NVT.
Changes in Pneumococcal Carriage Density Following
Vaccination
The highest mean density was observed in the prevaccination
survey, except for VT in vaccinated villages, where density was
highest in CSS-3 (Figure 3). As conﬁdence intervals were very
wide, further analysis was performed on pooled results from the
3 postvaccination surveys. A comparison of the mean densities
of VT and NVT carriage between all postvaccination CSSs and
the baseline CSS is shown in Table 3. In the vaccinated villages,
there was a signiﬁcant decrease in the density of carriage with
any pneumococcus following vaccination in individuals older
than 5 years (from 2.44 to 1.88; difference =−0.56; P = .001)
and a decrease of borderline signiﬁcance among the younger
age group (from 2.57 to 2.11; difference =−0.46; P = .07)
(Table 3A). In the control villages, there was also a decrease in
density following vaccination, both among the older individuals
(from 2.44 to 1.75; difference =−0.69; P = .001), as well as
among the younger individuals (from 2.76 to 1.99; difference =
Table 1. Number of Samples Tested for Pneumococcal Carriage
Density Data in Prevaccination and Postvaccination Cross-
sectional Surveys
Survey Samples, No.
Pneumococcal
Colonization,
No. (%)
Density
Available,
No. (%)
Prevaccination 2094 1488 (71) 1390a (93)
Postvaccination
CSS-1 1109 511 (46) 508 (>99)
CSS-2 1155 426 (37) 425 (>99)
CSS-3 434 250 (58) 239 (96)
Overall 4792 2675 (48) 2562 (96)
Abbreviation: CSS, cross-sectional survey.
a Fifty samples were from children <30 months of age, an age group not
included in the postvaccination surveys.
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−0.78; P = .002) (Table 3B). Similar decreases in density follow-
ing vaccination were observed for colonization with both VT
and NVT pneumococci (Tables 3A and B). Approximately 50%
and 40% of pneumococcal carriers had a density of carriage of
>1 in the postvaccination surveys (Figure 2).
Although serotype distribution within VT and NVT varied
between prevaccination and postvaccination surveys, this vari-
ation would account for <5% of the difference in mean
density observed in the comparisons (data not shown).
Comparison of Pneumococcal Carriage Density Between
Vaccinated and Control Groups in the Postvaccination Surveys
Mean densities in the postvaccination surveys among children
≤5 years of age were 1.99 and 2.11 in the control and vacci-
nated groups, respectively, and among individuals aged >5
years were 1.75 and 1.88, respectively. Differences between the
vaccinated and control groups were not statistically signiﬁcant
for any of the comparisons (Table 4).
DISCUSSION
To the best of our knowledge, this is the ﬁrst extensive com-
munity study to measure the density of pneumococcal naso-
pharyngeal carriage. The data were collected as part of a CRT
conducted in rural Gambia, an area with a high prevalence of
pneumococcal nasopharyngeal carriage [14]. We evaluated the
density of pneumococcal carriage in different age groups
before and after PCV-7 vaccination. Our main ﬁnding was
that the density of pneumococcal carriage decreased with in-
creasing age. We also showed in a before-after analysis that
the density of pneumococcal carriage was lower after
vaccination.
We have shown a strong inverse correlation between
pneumococcal nasopharyngeal density and age, which is in
agreement with the fact that the overall prevalence of pneumo-
coccal carriage falls with increasing age [14, 21–23]. Younger
individuals have a higher prevalence of nasopharyngeal
Figure 1. Mean density of pneumococcal carriage by age in the prevaccination cross-sectional survey. Age groups considered for the ﬁgure were
0–<2.5 years, 2.5–5 years, 6–9 years, 10–19 years, 20–39 years, and ≥40 years. Triangles represent mean density for each age group (plotted at the
midpoint), and capped lines are 95% conﬁdence intervals. Abbreviations: NVT, non–vaccine-type pneumococci; VT, vaccine-type pneumococci.
Table 2. Age and Sex Distribution of Pneumococcal Carriers in the Different Cross-sectional Surveys
Prevaccination Postvaccination
Control Communities Vaccinated Communities Control Communities Vaccinated Communities
Male sex, % 51.28 45.82 50.51 51.04
Age, years, median (IQR) 13.5 (7.5–34.0) 13.5 (7.5–29.5) 10.5 (6.5–18.5) 11.2 (6.3–20.4)
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pneumococcal carriage and, at the same time, a higher density
of pneumococci in the nasopharynx. This may be due in part
to less close contact between adults than between young chil-
dren, but it is also likely to be due to the progressive acquisi-
tion of immunity as a result of prior pneumococcal carriage.
Immunity acquired by prior pneumococcal exposure may
prevent colonization and also bring a quick decrease in
density of infection that, in turn, leads to accelerated clearance,
as observed in mouse models [24]. Several mechanisms might
be responsible for the naturally acquired immune response
that protects against carriage and reduces carriage density.
Some studies have shown a negative association between the
presence of antibodies to individual pneumococcal polysac-
charides and the risk of subsequent acquisition of pneumococ-
ci of that serotype [25, 26]. In our study, we were not able to
match antibody concentrations to the prevalence of carriage at
Figure 2. Distribution of pneumococcal carriage density among infected individuals before (Pre Vacc) and after (Post Vacc) vaccination, in Vaccinated
and Control groups. A, Children ≤5 years of age when the sample was collected. B, Individuals >5 years of age when the sample was collected.
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the individual level. However, antibody concentrations
reached a plateau in the study villages at approximately 10
years of age (Ota et al, unpublished data), while the decrease
in the prevalence of pneumococcal carriage [12] and the pneu-
mococcal density continued beyond this age, suggesting that
other non–serotype-speciﬁc mechanisms, such as acquisition
of humoral or cellular immune responses (ie, interleukin 17
release [17]) to conserved antigens, are involved in this
process [27–29]. The occurrence of the highest density of car-
riage in young children might explain, at least in part, why
child carriers transmit pneumococcal infection more efﬁcient-
ly than adults, as we have shown in our study community [30]
Figure 3. Mean density of vaccine-type (triangles) and non–vaccine-type (circles) pneumococcal carriage at prevaccination (0) and at 3 postvaccination
surveys (CSS-1 to CSS-3). Capped lines represent 95% conﬁdence intervals. A, Children ≤5 years of age when the sample was collected. B, Individuals
>5 years of age when the sample was collected. Abbreviation: CSS, cross-sectional survey.
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Table 3. Mean Density of Pneumococcal Carriage in Infected Individuals During the Prevaccination and Postvaccination Cross-Sectional Surveys in Vaccinated Villages and
Control Villages, by Age at Sample Collection
Age≤ 5 Years Age > 5 Years
Study Arm, Serotype Group Prevaccination Postvaccinationa Difference (95% CI) P Prevaccination Postvaccinationa Difference (95% CI) P P int
b
Vaccinated villages
VT 2.87 2.48 −0.39 (−0.82 to 0.04) .071 2.14 1.78 −0.36 (−0.64 to −0.07) .021 .902
NVT 2.72 2.08 −0.64 (−1.28 to 0.01) .052 2.48 1.91 −0.57 (−0.90 to −0.25) .003 .582
All 2.57 2.11 −0.46 (−0.97 to 0.04) .067 2.44 1.88 −0.56 (−0.83 to −0.29) .001 .702
Control villages
VT 2.70 1.94 −0.76 (−1.49 to −0.04) .042 2.42 1.78 −0.64 (−1.00 to −0.28) .003 .685
NVT 2.90 2.03 −0.87 (−1.46 to −0.28) .010 2.45 1.74 −0.71 (−1.06 to −0.36) .001 .895
All 2.76 1.99 −0.78 (−1.19 to −0.36) .002 2.44 1.75 −0.69 (−1.01 to −0.37) .001 .696
Data are mean densities, expressed in arbitrary units, as defined in the Methods section.
Abbreviations: CI, confidence interval; NVT, non–vaccine-type pneumococci; VT, vaccine-type pneumococci.
a Data are for all 3 postvaccination cross-sectional surveys combined.
b P value for interaction between group (control or vaccinated) and age category.
Table 4. Comparison of Mean Density of Pneumococcal Carriage in Infected Individuals During the 3 Postvaccination Cross-Sectional Surveys in Vaccinated and Control Villages,
by Age at Sample Collection
Age≤ 5 Years Age > 5 Years
Serotype Group Control Villages Vaccinated Villages Difference Differenceadj
a (95% CI) P Control Villages Vaccinated Villages Difference Differenceadj
a (95% CI) P P int
b
VT 1.94 2.43 0.49 0.53 (−0.03 to 1.08) .060 1.78 1.78 0.00 0.15 (−0.24 to 0.54) .435 .102
NVT 2.04 2.07 0.03 −0.09 (−0.61 to 0.44) .738 1.74 1.91 0.17 0.17 (−0.01 to 0.35) .062 .582
All 1.99 2.11 0.12 0.13 (−0.34 to 0.60) .579 1.75 1.88 0.13 0.13 (−0.04 to 0.30) .135 .981
Data are mean densities, expressed in arbitrary units, as defined in the Methods section.
Abbreviations: CI, confidence interval; NVT, non–vaccine-type pneumococci; VT, vaccine-type pneumococci.
a Adjusted for baseline density.
b P value for interaction between group (control or vaccinated) and age category.
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and as has been detected elsewhere [4, 31, 32]. Reduction in
high-density carriage among young children by vaccination
may contribute to the vaccine’s herd effect.
The usefulness of measurement of the density of pneumo-
coccal carriage in the nasopharynx as a tool for the diagnosis
of pneumococcal pneumonia is of current interest [6]. Bacteri-
al densities are increased among pneumonic individuals, com-
pared with healthy controls [6, 11]. Our ﬁndings indicate that
if the ratio of carriage density between a case of suspected
pneumonia and a healthy asymptomatic carrier is to be used
as a diagnostic test, the impact of age on carriage density will
have to be taken into account in setting “normal” values.
We have shown previously that vaccination with PCV-7
lowered the prevalence of nasopharyngeal VT carriage in both
fully vaccinated communities and in those in which only chil-
dren younger than 30 months received PCV-7, suggesting that
young children are the main drivers of carriage in the commu-
nity as a whole [12]. The results of the current study, which
showed reductions in the density of VT carriage in vaccinated
and control communities (in which only part of the popula-
tion was vaccinated), are in keeping with this hypothesis and
in agreement with the ﬁndings from a CRT conducted in a
Navajo population, in which the density of pneumococcal car-
riage (also measured as a semiquantitative variable) among
vaccinated children was almost 40% lower than that among
unvaccinated children [33]. Reduction in density is also in
agreement with the hypothesis stated above, which asserted
that accelerated clearance (that would lead to a shift to a lower
density of carriage) rather than inhibition of colonization may
be an important mechanism of protection against pneumococ-
cal carriage acquired either through natural exposure or
through vaccination [24]. If reduction in the density of car-
riage results in less effective transmission, as seem likely, this
could be an important mechanism through which PCVs exert
an indirect protective herd effect. We did not ﬁnd any signiﬁ-
cant difference in carriage density between subjects from full
or partially vaccinated communities, contrasting with the ﬁnd-
ings in relation to the prevalence of VT carriage, in which dif-
ferences between study arms were small but statistically
signiﬁcant in some of the comparisons [12].
An anomalous ﬁnding was the detection of a reduction in
the density of NVT carriage following vaccination. Because we
do not expect any direct effect of PCV-7 vaccination on sero-
types not included in the vaccine, alternative explanations are
needed. One possibility is that the decrease in density of NVT
was a consequence of the unmasking of low-density NVT
after the removal VT as a result of vaccination. Some investi-
gators have suggested that the observed increase of NVT naso-
pharyngeal carriage after vaccine introduction is an artifact of
unmasking, in which the reduction in the prevalence of VT
makes it easier to detect NVT present in the population that
were undetected in the absence of vaccination [6, 9]. Because
the commonly used serotyping methods evaluate only a
limited number of colonies, investigators may fail to detect co-
colonization with serotypes present at low density. In the CRT
discussed above conducted in a Navajo population [33], inves-
tigators found a decrease in the prevalence and density of VT
but not of NVT in the vaccinated arm. In that study, the sero-
typing method was more sensitive than ours, making unmask-
ing less likely. Another possible explanation for our ﬁndings
of a reduction in the density of NVT carriage after vaccination
is that there were some secular trends unrelated to vaccination.
However, it is difﬁcult to envisage what changes could have
occurred in the study villages that could have affected the
density of carriage during the conduct of the study, because
there were no signiﬁcant climatic or social variations during
the study period or changes in medical practice, apart from
the administration of azithromycin at the time of the last CSS,
an event that has been addressed in the analysis. The methods
by which samples were collected, stored, and tested were
identical in all CSSs, and quality controls were in place
through the study. Any secular change affecting density
should probably have had the same impact on the density of
NVT and VT.
The analysis presented here has additional limitations.
Density was measured as a semiquantitative and subjective
variable, but technicians were blind as to which study group a
sample belonged. Newer methods (eg, real-time polymerase
chain reaction) are able to provide fully quantitative measure-
ments and are likely to make measurement of bacterial density
a more feasible end point for vaccine trials than has been the
case in the past. Because of the heterogeneity of the results of
the different postvaccination surveys, we averaged the results
for the main analysis. In addition, analysis was oversimpliﬁed
by grouping serotypes in 2 groups (VT and NVT). Density
differs by serotype and serotype distribution within VT and
NVT varied in the pre vs the postvaccination CSSs. However,
such variation has not signiﬁcantly altered the mean densities
in the comparisons (data not shown).
In summary, our analysis has given insights into why chil-
dren are more efﬁcient than adults in pneumococcal transmis-
sion when they are nasopharyngeal carriers. Our time-trends
analysis also shows that vaccination may lower the density of
pneumococcal carriage in wholly and partially vaccinated
communities. Further studies to support or disprove our ﬁnd-
ings of an effect of vaccination on NVT are needed.
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